Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 28;13:1182558. doi: 10.3389/fonc.2023.1182558

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Michaux, Perrier, Mehlman, Alshehhi, Dubois, Lacave, Coulet, Cadranel and Fallet

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Case 1: timeline illustrating the changes in therapeutic regimen in correlation with molecular and radiological findings. FISH, fluorescence in situ hybridization; dPCR, digital polymerase chain reaction; TTF, time to treatment failure; Mo., months; ctDNA, circulating tumor DNA; IHC, immunohistochemestry; NGS, next-generation sequencing; Brigatinib 180, brigatinib with a 180-mg daily dose regimen; B240, brigatinib with a 240-mg daily dose regimen; A+O, combined treatment with alectinib and osimertinib. In red, the treatments used when EGFR resistance mutation was identified.